SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (29)7/21/2000 12:18:54 AM
From: Pseudo Biologist  Read Replies (1) | Respond to of 1022
 
Well, it seems the 25-th anniversary of MAbs was just about a week ago. Here is a story:

ftmarketwatch.com{20D0250B-463D-4D57-ABD5-D4014279189D}

PB



To: Pseudo Biologist who wrote (29)7/21/2000 9:52:55 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 1022
 
re. "Clark" discussion.....

Patients have been receiving massive exposure to allotypes for ages, both subcutaneously and intravenously. Patients who have rec'd polyclonals derived from plasma certainly don't address the anti-id issue, but are they sensitized to allotypes?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News